Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

Area of Science:

• Molecular Biology
• Cancer Research
• Metabolic Engineering

Background:

• DNA damage resistance is a significant obstacle to successful DNA-damaging therapies in multiple myeloma (MM).
• Interleukin enhancer binding factor 2 (ILF2), a DNA damage regulator, is overexpressed in a majority of MM patients with refractory disease.
• Antisense oligonucleotide (ASO) therapy targeting ILF2 is being investigated for MM treatment.

Purpose of the Study:

• To elucidate the mechanisms by which multiple myeloma cells acquire resistance to DNA-damaging therapies, specifically ILF2 ASO.
• To identify key molecular players involved in MM cell adaptation and survival under DNA damage stress.

Main Methods:

• Utilized CRISPR/Cas9 screening to identify genes essential for MM cell survival during ILF2 ASO treatment.
• Investigated metabolic rewiring in MM cells in response to DNA damage.
• Assessed the role of the mitochondrial DNA repair protein DNA2 in counteracting DNA damage.

Main Results:

• Multiple myeloma cells exhibit adaptive metabolic rewiring to maintain energy balance and promote survival upon DNA damage.
• Loss of function of the mitochondrial DNA repair protein DNA2 significantly impairs MM cells' ability to overcome ILF2 ASO-induced DNA damage.
• DNA2 is identified as essential for counteracting oxidative DNA damage in MM cells.

Conclusions:

• MM cells exploit metabolic adaptation to survive DNA-damaging insults.
• The mitochondrial DNA repair protein DNA2 is crucial for MM cell resistance to DNA damage.
• Targeting DNA2 represents a potential therapeutic strategy to exploit the metabolic vulnerability of MM cells.